Effect of Endothelin-Receptor Antagonists on Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage Remains Unclear | Zendy

Mervyn D.I. Vergouwen | Zendy

Open Access

Effect of Endothelin-Receptor Antagonists on Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage Remains Unclear

Author(s) -

Mervyn D.I. Vergouwen

Publication year - 2009

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.109.565887

Subject(s) - medicine , subarachnoid hemorrhage , vasospasm , ischemia , cerebral vasospasm , endothelin receptor , cerebral infarction , endothelin receptor antagonist , anesthesia , brain ischemia , cardiology , receptor

To the Editor:With great interest I have read the recent meta-analysis on the effect of endothelin-receptor antagonists (ETRAs) in patients with aneurysmal subarachnoid hemorrhage.1 Because endothelin might have an important function in the pathogenesis of radiographic vasospasm, ETRAs are presently under intensive investigation in this group of patients. Recently, the results of a large double-blind, placebo-controlled Phase II study (Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage [CONSCIOUS-1]) investigating the effect of the ETRA clazosentan in patients with aneurysmal subarachnoid hemorrhage for the first time revealed a 65% relative risk reduction (95% CI, 47% to 78%) of angiographically demonstrated vasospasm in the group of patients treated with the highest dose of clazosentan (15 mg/h).2 This finding was impressive, because no other drug ever before was found …

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research